Effect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree®) in Adults
Zhao Wang, Toyin Adewole, Lilian W Adeojo, Peibing Qin, Stefan Schwabe, Azmi Nasser · 2026
Read Effect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree®) in Adults by Zhao Wang, Toyin Adewole, Lilian W Adeojo, Peibing Qin, Stefan Schwabe, Azmi Nasser (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13612620.txt.
Description
Zhao Wang and colleagues report a 2026 study of how liver problems affect the way the body handles viloxazine. Viloxazine is a non-stimulant drug used for attention deficit hyperactivity disorder in children and adults. Adults with mild, moderate, or severe liver impairment each took one dose of the extended-release capsule form, sold as Qelbree, and were compared with matched adults whose livers worked normally.
Blood tests over 72 hours showed that drug exposure stayed within about a quarter of the level seen in the control group at every level of liver damage. The drug did leave the body more slowly when liver damage was moderate or severe. Side effects were few, mostly headache and sleepiness, and the authors conclude that liver impairment alone does not call for a blanket change in dose.
Catalog record
| CREATOR | Zhao Wang, Toyin Adewole, Lilian W Adeojo, Peibing Qin, Stefan Schwabe, Azmi Nasser |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |